Factors Associated with Plasma IL-6 Levels during HIV Infection

Journal of Infectious Diseases

Volumn 212, Issue 4, 2015, Pages 585-595

  Borges, Álvaro H ^a   O'Connor, Jemma L ^b   Phillips, Andrew N ^b   Rönsholt, Frederikke F ^a   Pett, Sarah ^b,c   Vjecha, Michael J ^d   French, Martyn A ^e,f   Lundgren, Jens D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

Author keywords

cancer; cardiovascular disease; HIV; IL 6; inflammation

Indexed keywords

ABACAVIR; ABACAVIR PLUS EMTRICITABINE; ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR; ATAZANAVIR; DIDANOSINE; DIDANOSINE PLUS EMTRICITABINE; DIDANOSINE PLUS LAMIVUDINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR; EMTRICITABINE PLUS ZIDOVUDINE; FOSAMPRENAVIR; INDINAVIR; INTERLEUKIN 6; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; AGING; ARTICLE; BLACK PERSON; BODY MASS; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; EDUCATIONAL STATUS; FACTORIAL ANALYSIS; FEMALE; GLOMERULAR DYSFUNCTION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERLEUKIN 6 BLOOD LEVEL; KIDNEY FUNCTION TEST; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; VIRUS REPLICATION; BLOOD; COMPLICATION; INFLAMMATION; METABOLISM; MIDDLE AGED; VIRUS LOAD;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; RNA, VIRAL; SMOKING; VIRAL LOAD;

EID: 84939605194     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv123     Document Type: Article

References (50)

1. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265:621-36.
2. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res 2014; 2:288-94.
3. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003; 24:25-9.
4. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6:583-8.
5. Nakajima K, Martínez-Maza O, Hirano T, et al. Induction of IL-6 (B cell stimulatory factor-2/IFN-beta 2) production by HIV. J Immunol 1989; 142:531-6.
6. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990; 144:480-4.
7. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-95.
8. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55:126-36.
9. Raj DS. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum 2009; 38:382-8.
10. Borges AH, Weitz JI, Collins G, et al. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviraltreated HIV disease. AIDS 2014; 28:1791-6.
11. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70:104-8.
12. Borges ÁH, Silverberg MJ, Wentworth D, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 2013; 27:1433-41.
13. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) ConsortiumHingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379:1214-24.
14. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7: e44454.
15. Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3:e000844.
16. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106:506-12.
17. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
18. Peters L, Neuhaus J, Duprez D, et al. Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. J Clin Virol 2014; 60:295-300.
19. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96.
20. Abrams D, Lévy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-59.
21. Borges AH, O'Connor JL, Phillips AN, et al. Factors associated with Ddimer levels in HIV-infected individuals. PLoS One 2014; 9:e90978.
22. Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the Strategic Management of Antiretroviral Therapy (SMART) study. Clin Infect Dis 2008; 47:1468-75.
23. Peters L, Neuhaus J, Mocroft A, et al. Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. Antivir Ther 2011; 16:667-75.
24. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-12.
25. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22:1668-73.
26. Salter ML, Lau B, Mehta SH, Go VF, Leng S, Kirk GD. Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections. J Acquir Immune Defic Syndr 2013; 64:488-95.
27. Lacerda HR, Falcaõ Mda C, de Albuquerque VM, et al. Association of inflammatory cytokines and endothelial adhesion molecules with immunological, virological, and cardiometabolic disease in HIV-infected individuals. J Interferon Cytokine Res 2014; 34:385-93.
28. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-55.
29. Fernández-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000; 85:1334-9.
30. Koethe JR, Dee K, Bian A, et al. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses 2013; 29:1019-25.
31. Straub RH, Hense HW, Andus T, Schölmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 2000; 85:1340-4.
32. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82:4196-200.
33. Pal M, Febbraio MA, Whitham M. From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation. Immunol Cell Biol 2014; 92:331-9.
34. Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001; 86:1154-9.
35. Peters MJ, Ghouri N, McKeigue P, Forouhi NG, Sattar N. Circulating IL-6 concentrations and associated anthropometric and metabolic parameters in South Asian men and women in comparison to European whites. Cytokine 2013; 61:29-32.
36. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10: e1004078.
37. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26:1371-85.
38. Martínez E, D'Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavirboosted protease inhibitors to raltegravir. AIDS 2012; 26:2315-26.
39. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41:1787-93.
40. Bonora S, Nicastri E, Calcagno A, et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009; 81:400-5.
41. Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS 2012; 26:475-81.
42. Tappia PS, Troughton KL, Langley-Evans SC, Grimble RF. Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci 1995; 88:485-9.
43. Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol 1999; 36:67-72.
44. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:327-34.
45. Liuzzo G, Biasucci LM, Gallimore JR, et al. Enhanced inflammatory response in patients with pre infarction unstable angina. J Am Coll Cardiol 1999; 34:1696-703.
46. Fuster D, Tsui JI, Cheng DM, et al. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. AIDS Res Hum Retroviruses 2013; 29:1110-6.
47. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107:87-92.
48. Veldhuis GJ, Willemse PH, Sleijfer DT, et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 1995; 13:2585-93.
49. French MA, Cozzi-Lepri A, Arduino RC, Johnson M, Achhra AC, Landay A; for the INSIGHT SMART Study Group. Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS 2015; 29:847-51.
50. Kline RB. Principles and practice of structural equation modelling. 2nd ed. New York, NY: Guilford Press, 2005.